SG11201510740YA - Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment - Google Patents

Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment

Info

Publication number
SG11201510740YA
SG11201510740YA SG11201510740YA SG11201510740YA SG11201510740YA SG 11201510740Y A SG11201510740Y A SG 11201510740YA SG 11201510740Y A SG11201510740Y A SG 11201510740YA SG 11201510740Y A SG11201510740Y A SG 11201510740YA SG 11201510740Y A SG11201510740Y A SG 11201510740YA
Authority
SG
Singapore
Prior art keywords
compositions
immune responses
cancer treatment
inducing immune
carbohydrate vaccine
Prior art date
Application number
SG11201510740YA
Other languages
English (en)
Inventor
Cheng-Der Tony Yu
Cheng-Chi Irene Wang
Wei-Han Lee
Yu-Chen Lin
Yu-Hsin Tom Lin
I-Ju Chen
Original Assignee
Obi Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Pharma Inc filed Critical Obi Pharma Inc
Publication of SG11201510740YA publication Critical patent/SG11201510740YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001173—Globo-H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SG11201510740YA 2013-09-17 2014-09-15 Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment SG11201510740YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361878982P 2013-09-17 2013-09-17
PCT/IB2014/002744 WO2015159118A2 (fr) 2013-09-17 2014-09-15 Compositions de vaccin à base de glucides permettant d'induire des réponses immunitaires et utilisations associées dans le traitement du cancer

Publications (1)

Publication Number Publication Date
SG11201510740YA true SG11201510740YA (en) 2016-01-28

Family

ID=53935288

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201510740YA SG11201510740YA (en) 2013-09-17 2014-09-15 Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment

Country Status (19)

Country Link
US (1) US20150297696A1 (fr)
EP (1) EP3046588B1 (fr)
JP (1) JP6431920B2 (fr)
KR (1) KR20160055861A (fr)
CN (1) CN105764921B (fr)
AR (1) AR097661A1 (fr)
AU (2) AU2014391422A1 (fr)
BR (1) BR112015032713B1 (fr)
CA (1) CA2924286C (fr)
CL (1) CL2016000538A1 (fr)
ES (1) ES2914176T3 (fr)
HK (2) HK1221476A1 (fr)
IL (1) IL242907B (fr)
NZ (1) NZ714555A (fr)
PH (1) PH12015502629B1 (fr)
RU (1) RU2666141C2 (fr)
SG (1) SG11201510740YA (fr)
TW (1) TWI641383B (fr)
WO (1) WO2015159118A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2943334A1 (fr) 2014-03-19 2015-09-24 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Glycopeptides immunogenes, composition comprenant les glycopeptides et leur utilisation
SG11201702037SA (en) * 2014-09-15 2017-04-27 Obi Pharma Inc Immunogenic/therapeutic glycoconjugate compositions and uses thereof
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
CN109311995A (zh) 2016-03-29 2019-02-05 台湾浩鼎生技股份有限公司 抗体、药物组合物和方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018071683A2 (pt) 2016-04-22 2019-02-19 Obi Pharma, Inc. método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
AU2017302038B2 (en) 2016-07-27 2024-03-21 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
WO2018023121A1 (fr) 2016-07-29 2018-02-01 Obi Pharma, Inc. Anticorps humains, compositions pharmaceutiques et procédés
TW201825522A (zh) * 2016-09-23 2018-07-16 張志隆 抗-globo h 抗體
CA3044274A1 (fr) 2016-11-21 2018-05-24 Obi Pharma, Inc. Molecules biologiques conjuguees, compositions pharmaceutiques et procedes
CA3101517A1 (fr) * 2018-06-01 2019-12-05 Obi Pharma, Inc. Polytherapie utilisant un anticorps anti-globo h ou anti-ssea -4 avec un anticorps des points de controle immunitaire anti-negatif
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
CN112924700A (zh) * 2021-01-26 2021-06-08 海南医学院 一种钥孔血蓝蛋白(KLH)的包被工艺及小鼠KLH特异性IgG抗体定量检测试剂盒
EP4327821A1 (fr) * 2021-05-24 2024-02-28 Cha Vaccine Research Institute Co., Ltd Composition thérapeutique d'immuno-oncologie utilisant un adjuvant comprenant des lipopeptides et du poly (i:c)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU519567B2 (en) * 1977-07-13 1981-12-10 Akzo Nv Psychopharmacological penta and hexa-peptides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
US6544952B1 (en) * 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
JP2004534088A (ja) * 2001-07-06 2004-11-11 スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ 癌のための多価コンジュゲートワクチン
WO2003015796A1 (fr) * 2001-08-14 2003-02-27 Biomira, Inc. Conjugue immunogene d'haptenes glucidiques et support proteique agrege
CA2537161C (fr) * 2003-08-25 2014-07-29 Oncomune Vaccin preventif contre le cancer a base de molecule boris (frere du regulateur de sites marques)
BRPI0706788A2 (pt) * 2006-01-31 2011-04-05 Novartis Ag anticorpos antagonistas il-17
WO2009044918A1 (fr) * 2007-10-05 2009-04-09 Takeda Pharmaceutical Company Limited Dérivé de neuromédine u
EP2268315B1 (fr) * 2008-03-31 2019-07-31 Freie Universität Berlin Conjugués de médicaments avec polyglycérols
NZ604089A (en) * 2010-06-11 2015-03-27 Sloan Kettering Inst Cancer Multivalent glycopeptide constructs and uses thereof
EP2500035A1 (fr) * 2011-03-15 2012-09-19 Icon Genetics GmbH Formule pharmaceutique contenant de l'immunoglobuline
KR101972303B1 (ko) * 2011-06-10 2019-04-25 메르사나 테라퓨틱스, 인코포레이티드 단백질-중합체-약물 접합체

Also Published As

Publication number Publication date
EP3046588A4 (fr) 2017-05-31
HK1222569A1 (zh) 2017-07-07
ES2914176T3 (es) 2022-06-07
AU2019200314A1 (en) 2019-02-07
AU2019200314B2 (en) 2020-07-02
AU2014391422A1 (en) 2015-12-17
JP6431920B2 (ja) 2018-11-28
CL2016000538A1 (es) 2016-10-28
PH12015502629A1 (en) 2016-03-07
CN105764921A (zh) 2016-07-13
US20150297696A1 (en) 2015-10-22
EP3046588B1 (fr) 2022-03-02
EP3046588A2 (fr) 2016-07-27
TWI641383B (zh) 2018-11-21
AR097661A1 (es) 2016-04-06
NZ714555A (en) 2020-03-27
WO2015159118A2 (fr) 2015-10-22
RU2666141C2 (ru) 2018-09-06
CA2924286C (fr) 2022-06-21
PH12015502629B1 (en) 2016-03-07
HK1221476A1 (zh) 2017-06-02
BR112015032713B1 (pt) 2023-03-21
IL242907B (en) 2020-11-30
JP2016540099A (ja) 2016-12-22
KR20160055861A (ko) 2016-05-18
BR112015032713A2 (pt) 2018-03-20
CA2924286A1 (fr) 2015-10-22
TW201521766A (zh) 2015-06-16
RU2015150769A (ru) 2017-10-23
CN105764921B (zh) 2020-06-30
WO2015159118A3 (fr) 2016-03-17

Similar Documents

Publication Publication Date Title
HK1222569A1 (zh) 用於誘導免疫反應的糖疫苗組合物及其治療癌症的用途
HK1216991A1 (zh) 癌疫苗及使用其的治療方法
HK1218928A1 (zh) 癌症疫苗及接種方法
HK1222097A1 (zh) 用於吞嚥困難患者的營養的組合物
IL286759A (en) Therapeutic methods and preparations
ZA201508948B (en) Phenol derivative and preparation method and use in medicine thereof
HK1252695A1 (zh) 用於消除對治療劑的免疫應答的改進方法和化合物
IL251120B (en) Immunogenic/therapeutic glycoside preparations and their uses
HK1218880A1 (zh) 增强對艾美球蟲的免疫應答或限制艾美球蟲感染的組合物和方法
IL244354A0 (en) Flu vaccine and treatment
EP2956164A4 (fr) Vaccins contre le cancer ovarien et méthodes de vaccination
HK1248253A1 (zh) 對修飾的自體表位的抗腫瘤免疫應答
EP2892554A4 (fr) Compositions de stimulation immunitaire du vih comprenant des pili exprimés de façon recombinante sur des bactéries, et procédés associés
PL3129057T3 (pl) Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu
EP2934578A4 (fr) Vaccins pour traiter le cancer et compositions pour améliorer l'efficacité des vaccins
EP3143036C0 (fr) Conjugués thérapeutiques à base de par-1 et utilisations correspondantes
HUE050547T2 (hu) Oligoszaccharid konjugátumok és alkalmazási eljárások
HK1216860A1 (zh) 單次高劑量的 在新生兒和嬰兒中誘導保護性免疫反應
EP2968398A4 (fr) Hyaluronane modifié et ses utilisations dans le traitement du cancer
GB201322958D0 (en) Uses of oligouronates in cancer treatment
GB201319255D0 (en) Therapeutic compositions and methods
GB201320958D0 (en) Improvements in and relating to medical devices
GB201309059D0 (en) Improvements in and relating to food shaping devices